Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

Status Completed

Clinical Trial Summary

Methamphetamine dependence is a serious public health problem, with methamphetamine abusers being at risk for significant morbidity and mortality, including HIV. To date, no medication or psychotherapeutic strategy has shown robust, long-term efficacy in treating this disorder. This clinical trial will examine whether lisdexamfetamine shows promise in alleviating withdrawal symptoms and preventing relapse relative to placebo in recently-abstinent methamphetamine dependent individuals. Findings of this study will not only shed light on whether lisdexamfetamine may improve upon treatment for this disorder but also inform future medication development strategies for improving treatment for drug dependence disorders. Discovering efficacious limited risk interventions that show more robust, longer-term outcomes would be beneficial both to the individual and society.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Methamphetamine Dependence

Clinical Trial Details

NCT number	NCT02034201
Study type	Interventional
Source	University of Arkansas
Contact
Status	Completed
Phase	Phase 1
Start date	February 2014
Completion date	May 19, 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01813656` - An Study of Aripiprazole in the Treatment of Methamphetamine Dependence	Phase 4
Completed	`NCT00984360` - Study of Naltrexone for Methamphetamine Addiction	Phase 2
Completed	`NCT01685463` - Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving	N/A
Completed	`NCT00569374` - Safety and Tolerability of Modafinil for Methamphetamine Dependence	Phase 2
Completed	`NCT01967381` - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse	Early Phase 1
Completed	`NCT01354470` - A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence	Phase 2
Active, not recruiting	`NCT01044238` - Methylphenidate to Treat Methamphetamine Dependence	Phase 2
Completed	`NCT01215929` - Studying Amphetamine Withdrawal in Humans	Phase 2
Terminated	`NCT01019707` - Safety Assessment of Atomoxetine With MA IV Administration	Phase 1
Completed	`NCT00227123` - A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence	N/A
Recruiting	`NCT02568878` - Creatine for Depressed Male and Female Methamphetamine Users	Phase 3
Completed	`NCT01011829` - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	Phase 2
Completed	`NCT01007539` - Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence	Phase 3
Completed	`NCT01062451` - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT00687713` - Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence	Phase 2
Completed	`NCT01063205` - NAC as a Potential Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT02058966` - Pilot Study of Entacapone for Methamphetamine Abuse	Early Phase 1
Completed	`NCT00332605` - N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence	Phase 2
Completed	`NCT01860807` - Trial of Ibudilast for Methamphetamine Dependence	Phase 2
Terminated	`NCT01813643` - A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis	Phase 4